validating viQtor’s vital sign measurements
Validating viQtor’s vital sign measurements in Postoperative Patients: A study Utilizing Photoplethysmography (PPG) Sensor Technology.
Collaboration with: University Medical Center Utrecht (UMC Utrecht)
Study Overview
This single-center prospective observational study aims to train, refine, and validate a new respiratory rate (RR) algorithm for the viQtor device. It will also validate the improved SpO2, RR, and PR algorithms by comparing them with a reference device, specifically the Spacelabs XPREZZON® 91393. Conducted at UMC Utrecht, the study involves collecting continuous photoplethysmogram (PPG) data and vital parameters (PR, RR, and SpO2) from 80 postoperative patients over a period of 4 to 24 hours. Furthermore, the study will evaluate the technical performance of continuous monitoring with the viQtor device and assess patient satisfaction.
Key Participants
80 post-operative patients at the recovery room in UMC Utrecht.
Primary Objectives
To determine the accuracy of viQtor's measurements for Respiratory Rate (RR), Pulse Rate (PR), and SpO2 by comparing them with data obtained through ECG measurement from the reference device, Spacelab type XPREZZON® 91393 and only in phase 2 of the study, with the Smart Advanced Capno-Line® H Plus EtCO₂ sampling line (Med-tronic, Boulder, CO, USA) to achieve more precise RR measurements.
To assess user acceptability of the viQtor device using a 5-point Likert Scale questionnaire.
To evaluate the technical feasibility of the viQtor device in a post-operative setting.
Expected Results and Benefits
The study will provide insights into viQtor’s accuracy in capturing key vital signs in postoperative patients, and evaluate the device’s acceptability among users, guiding its potential use in clinical settings.
Study Duration
Start: April 2024
Duration: 11 months
Phase 1: Completed (N = 44)
Phase 2: Started in January 2025
Status: Ongoing. Final inclusion expected in Q1 2025